Achieve Life Sciences, Inc.
ACHV
$4.62
-$0.16-3.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 90.16% | 81.94% | 62.99% | 42.11% | 19.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.40% | 97.52% | 86.51% | 43.37% | -7.30% |
| Operating Income | -67.40% | -97.52% | -86.51% | -43.37% | 7.30% |
| Income Before Tax | -58.90% | -83.07% | -68.98% | -33.58% | 7.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.90% | -83.07% | -68.98% | -33.58% | 7.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.90% | -83.07% | -68.98% | -33.58% | 7.39% |
| EBIT | -67.40% | -97.52% | -86.51% | -43.37% | 7.30% |
| EBITDA | -67.90% | -98.40% | -87.28% | -43.73% | 7.32% |
| EPS Basic | -22.06% | -32.51% | -4.02% | 19.70% | 46.26% |
| Normalized Basic EPS | -24.52% | -33.38% | -4.09% | 20.16% | 48.11% |
| EPS Diluted | -22.06% | -32.51% | -4.02% | 19.70% | 46.31% |
| Normalized Diluted EPS | -24.52% | -33.38% | -4.09% | 20.16% | 48.11% |
| Average Basic Shares Outstanding | 34.83% | 35.98% | 59.59% | 61.79% | 60.39% |
| Average Diluted Shares Outstanding | 34.83% | 35.98% | 59.59% | 61.79% | 60.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |